应用遗传学和分子生物学分析评价伊马替尼和常规化疗治疗慢性粒细胞白血病的疗效

Efficiency evaluation of imatinib and traditional chemical therapy in patients with chronic myeloid leukemia by analysis of cytogenetics and molecular genetics

关键词:  慢性粒细胞白血病  Ph染色体  bcr-abl融合基因  伊马替尼

Key words:  chronic myeloid leukemia  Philadelphia chromosome  bcr-abl fusion gene  Imatinib

摘要:

[目的] 比较伊马替尼和常规化疗治疗慢性粒细胞白血病的疗效。[方法]收集20例慢性粒细胞白血病患者，其中11例应用伊马替尼治疗，9例应用常规化疗。采用常规染色体显带技术和半定量RT-PCR技术对细胞遗传学及分子遗传学进行动态监测，评价两种不同治疗方法的血液学、遗传学、分子生物学缓解率。[结果]应用伊马替尼治疗的患者均达血液学缓解，其中9例患者Ph染色体和bcr-abl融合基因消失，遗传学缓解率为81%。应用常规化疗的患者均能达到血液学缓解，但无一例达遗传学缓解。[结论]伊马替尼治疗慢性粒细胞白血病能达到部分或完全细胞遗传学缓解及分子生物学水平的缓解，优于常规化学药物治疗。

Abstract:

[Objective] To compare the efficiency of imatinib mesylate (imatinib) and traditional chemical therapy in patients with chronic myeloid leukemia (CML) in chronic phase．[Methods] Collecting 20 patients with chronic myeloid leukemia in chronic phase, 11 patients were treated with imatinib, while the other 9 were treated with traditional chemical therapy. Karyotypes were analyzed by chromosome G banding in 20 cases who were monitored the level of bcr-abl fusion gene by RT-PCR before and after administrating imatinib or traditional chemical therapy. Evaluate the rates of CHR, CyR, MoR. [Results] All the patients treated with imatinib got complete hematological response (CHR), 9 of which had negative ph chromosome and bcr-abl fusion gene. The cytogenetic response (CyR) response rate is 81％. To patients with traditional chemical therapy, CHR rate is 100%, but no one got CyR. [Conclusion] Imatinib significantly improves cytogenetic and molecular response rates of patients with chronic myeloid leukemia, which is better than traditional chemical therapy.